Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Economic Experts on Managed Care

Articles with lock require a subscription to GLG News | Request a free trial
Richard BalandOctober 14, 2008
Winners and losers in Healthcare IT
Analysis of: Stark Offers Bill to Hasten e-record Adoption | modernhealthcare.com
Author: Richard Baland, Partner, B2B CFO
This will soon be the best time in history to be selling Healthcare IT software and services. More money will be spent in the next three years than ever before. It may not be the best time for the staff at many hospitals. The staff are woefully unprepared for a quantum leap in Healthcare Technology
Steve DavisOctober 14, 2008
St. John's Wort: As good a s prescription drugs
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: Steve Davis, Director of Radiology, Clarendon Memorial Hospital Inc
St. John's Wort has been used for many years by herbalists to treat the symptoms of depression. Most herbal references I have reference it as a treatment for depression. The products are not regulated and therefore could contain different levels of the active ingredient. As well, the standard dosages...
October 13, 2008
This is not a study!
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: GLG Expert Contributor
The word "study" should not have appeared in the first sentence of the article.  What we have here is commonly known as a "meta-analysis".  A meta-analysis is nothing more than a simple tool that obviates the need to pull multiple studies to make one point or another. ...
Keith BermanSeptember 29, 2008
Highly Promising Phase III Trial of Baxter's IVIg for Alzheimer's Disease Begins
Analysis of: Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease | www.baxter.com
Author: Keith Berman, Consultant, Health Research Associates
Not surprisingly, everything tried thus far to slow the relentless progression of Alzheimer's disease has failed.  But if strong efficacy signals from two pilot studies and a recently completed Phase II trial of human immunoglobulin (IVIg) are confirmed in a Phase III trial scheduled to start next...
September 25, 2008
Narrowing the Category of "Carcinoma of Unknown Primary" Site-- still a ways to go
Analysis of: Raising the Profile of Cancer of Unknown Primary | jco.ascopubs.org
Author: GLG Expert Contributor
Diagnostic uncertainty in metastatic cancer as to the site of origin remains a problem in medicine today, albeit a slowly shrinking one. Immunohistochemistry using monoclonal antibodies from a host of makers will remain the mainstay in defining the site of origin, but it's proper use depends on accurate...
Keith BermanSeptember 17, 2008
Talecris IVIg Product Gets FDA Approval for Serious Neurological Disorder
Analysis of: FDA Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurolgoical Disorder CIDP in the US | www.talecris.com
Author: Keith Berman, Consultant, Health Research Associates
The efficacy of intravenous immunoglobulin (IVIg) for treatment of CIDP was documented many years ago.  Neurologists have ordered IVIg for years to treat this debilitating disorder, particularly for patients who fail therapy with corticosteroids or other immunosuppressive drugs. Talecris...
September 16, 2008
Updating Pricing on Brand to Generic Drugs are Timing and Inventory Issues for Payers and Providers
Analysis of: Medicare overpaid on drugs with new generics, report says | www.latimes.com
Author: GLG Expert Contributor
Payers in the private sector have historically tried to get providers to pay the generic price for branded multisource products using maximum allowable cost (MAC) terminology in their contracts as soon as the branded drugs have a generic source. This has caused problems for providers that still have...
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
August 28, 2008
Dangers of Methadone Usage
Analysis of: Dr. Mark Yergin testifies to Congress | www.nytimes.com
Author: William Fink, President, Managed Care Pharmacy Consultants, Inc
Doctors must be educated on the correct use of Methadone if unnecessary deaths are to be avoided.
Frederic GoldsteinAugust 26, 2008
Healthways A Market Downturn and Results
Analysis of: Healthways' Guidance Not So Healthy | www.forbes.com
Author: Frederic Goldstein, President and Chief Operating Officer, U.S. Preventive Medicine, Inc.
Healthways reported lower than expected earnings in its current quarter and analysts are pointing to a tightening in the healthcare markets and the fact that Healthways products are expensive. Does this really make sense?

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 527

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613